CSIMarket Company Name, Ticker, Customers, else..
 
Palatin Technologies Inc   (PTN)
Other Ticker:  
 
 
Price: $1.3700 $-0.02 -1.439%
Day's High: $1.415 Week Perf: -4.2 %
Day's Low: $ 1.34 30 Day Perf: -1.44 %
Volume (M): 89 52 Wk High: $ 5.65
Volume (M$): $ 121 52 Wk Avg: $2.16
Open: $1.36 52 Wk Low: $1.29



 Market Capitalization (Millions $) 22
 Shares Outstanding (Millions) 16
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 0

Palatin Technologies Inc
Palatin Technologies Inc. is a biopharmaceutical company based in Cranbury, New Jersey. It focuses on the development of peptide therapeutics for the treatment of various diseases and conditions. The company's main areas of focus include sexual dysfunction, cardiovascular disorders, inflammatory diseases, and dermatological conditions. Palatin Technologies is known for its development of a peptide drug called bremelanotide, which is used for the treatment of female sexual dysfunction. The company aims to bring innovative therapies to market that target unmet medical needs.


   Company Address: 4B Cedar Brook Drive Cranbury 8512 NJ
   Company Phone Number: 495?2200   Stock Exchange / Ticker: NYSE PTN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Palatin Technologies Inc

Palatin Technologies Inc Reports Larger Loss in January to March 31 2024 Financial Period Compared to Previous Year

Financial news report:
Palatin Technologies Inc reported a decrease in Diminishing Returns for the January to March 31 2024 financial period, with a figure of $-0.53 per share compared to $0.00 in the same period a year before. However, there was an improvement in Income per Share, which increased from $-0.56 per share in the previous reporting period.
The revenue for Palatin Technologies Inc remained unchanged at $0.00 million, compared to $1.20 million in the corresponding period a year before and $2.03 million sequentially. The net deficit for the January to March 31 2024 financial period was $-8.436 million, larger than the $-7.148 million reported a year ago.
Palatin Technologies Inc

Palatin Technologies Inc. Shakes the Pharmaceutical Industry with a Mix of Successes and Setbacks in Q4 2023



Palatin Technologies Inc, a leading pharmaceutical company specializing in innovative therapies, recently released its financial results for the October to December 31, 2023 quarter. The report unveils a combination of positive and negative indicators, sparking interest in how these results may impact the company in the future.
Shortfall per Share:
In the specified time frame, Palatin Technologies Inc experienced a shortfall per share of -$0.56 compared to no shortfall a year ago. Additionally, the company's shortfall increased from -$0.48 per share in the previous reporting season. This suggests that the company faced challenges in generating sufficient profits during this period.
Palatin Technologies Inc

Palatin Technologies Inc Outshines Competition with Exceptional Revenue Growth Amidst Industry Slump



As the financial landscape undergoes constant fluctuations, it is always intriguing to come across companies that manage to defy market norms and achieve exceptional results. Palatin Technologies Inc (PTN) is one such outlier, having recently announced an impressive revenue growth of 142.163% year-on-year to $2.11 million in the first quarter of 2024. This achievement is even more remarkable considering the Major Pharmaceutical Preparations sector, on average, experienced a decline of 4.79% in revenue during the same period.
Exceeding Expectations:
The recent financial results of PTN have surprised many, with the company recording top-line gains despite an industry-wide downturn. Not only did PTN manage to reverse the declining trend, but it also demonstrated a significant improvement in earnings per share (EPS) and revenue. EPS improved from $-0.98 per share in the previous reporting period, while revenue increased by 19.527% from $1.76 million.
Palatin Technologies Inc

Palatin Technologies Inc Defies the Odds with Explosive Revenue Growth in Q4 2023, While Major Pharmaceutical Preparations Companies Struggle to Turn Profitable

Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
Palatin Technologies Inc

Major Pharmaceutical Preparations Company Reports Extraordinary Financial Results, Fueling Optimism for Future Growth

Palatin Technologies Inc is a bio-pharmaceutical company that specializes in developing treatments for sexual dysfunction and other serious diseases. The recent earnings report for the third quarter of 2023 shows some promising growth for the company, with revenue advancing sharply by 453.305% to $1.20 million from $0.22 million in the similar financial reporting period a year before.
Despite the impressive revenue growth, the company reported a net loss of $-7.148 million, which is a slight improvement from the deficit of $-7.632 million in the same period a year ago. The loss can be attributed to the company's investment in research and development, which is a critical aspect of their business model.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com